Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-03-10FDA Approved: NINLARO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for NINLARO (ixazomib) submitted by Takeda Pharmaceuticals America, resulting in an updated approval…
-
FDA approval · 2021-03-09FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
The FDA approved a supplemental application for KYPROLIS (carfilzomib) submitted by Onyx Pharmaceuticals, Inc., marking an expansion of its …
-
FDA approval · 2021-02-08FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), updating or expanding its labeling.
-
FDA approval · 2021-01-15FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) from Janssen Biotech, Inc., updating the pr…
-
FDA approval · 2020-12-03FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for POMALYST (pomalidomide) submitted by Celgene Corporation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-10-20FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Zoledronic acid from Hikma Pharmaceuticals USA Inc., indicating regulatory approval for the spon…
-
EMA approval · 2020-07-24First antibody-drug conjugate for multiple myeloma patients with limited treatment options
The EMA announces the first antibody-drug conjugate approved for multiple myeloma patients with limited treatment options, offering a new ta…
-
FDA approval · 2020-05-14FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for POMALYST (pomalidomide) submitted by Celgene Corporation.
-
FDA approval · 2020-05-07FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
The FDA approved a supplemental application for KYPROLIS (carfilzomib) submitted by Onyx Pharmaceuticals, Inc. The approval updates the drug…
-
FDA approval · 2020-05-01FDA Approved: DARZALEX FASPRO — Original Application (Janssen Biotech, Inc.)
FDA approves DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) under an original application for treatment of adults with multiple myelom…
-
FDA approval · 2020-03-02FDA Approved: SARCLISA — Original Application (Sanofi-Aventis U.S. LLC)
The FDA approved Sarclisa (isatuximab) in its original application for adult patients with relapsed or refractory multiple myeloma, in combi…
-
FDA approval · 2020-02-21FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for Zoledronic acid from Dr. Reddy's Laboratories Limited, authorizing a generic product through…
-
FDA approval · 2020-02-21FDA Approved: NINLARO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for NINLARO (ixazomib) submitted by Takeda Pharmaceuticals America, Inc. The approval updates the pr…
-
FDA approval · 2020-02-21FDA Approved: ZOLEDRONIC ACID — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for zoledronic acid submitted by BluePoint Laboratories (ANDA205279).
-
FDA approval · 2019-12-04FDA Approved: THALOMID — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for Thalomid (thalidomide) submitted by Celgene Corporation.
-
FDA approval · 2019-10-30FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for POMALYST (pomalidomide) submitted by Celgene Corporation.
-
FDA approval · 2019-10-28FDA Approved: EMPLICITI — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
The FDA approved a supplemental application for EMPLICITI (elotuzumab) from E.R. Squibb & Sons, L.L.C., resulting in a labeling/indication u…
-
FDA approval · 2019-09-26FDA Approved: DARZALEX — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for DARZALEX (daratumumab) submitted by Janssen Biotech, Inc., resulting in changes to the product l…
-
FDA approval · 2019-09-13FDA Approved: MELPHALAN HYDROCHLORIDE — Original Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved the original application for MELPHALAN HYDROCHLORIDE from Qilu Pharmaceutical Co., Ltd., granting approval of its generic produ…
-
FDA approval · 2019-08-12FDA Approved: DOXORUBICIN HYDROCHLORIDE LIPOSOME — Supplemental Application (Baxter Healthcare Company)
FDA approved a supplemental application for doxorubicin hydrochloride liposome submitted by Baxter Healthcare Company.
-
FDA approval · 2019-07-03FDA Approved: XPOVIO — Original Application (Karyopharm Therapeutics Inc.)
The FDA approved XPOVIO (selinexor) from Karyopharm Therapeutics as a new drug application for the treatment of adult patients with relapsed…
-
FDA approval · 2019-05-30FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Mozobil (plerixafor) by Sanofi-Aventis U.S. LLC. The approval expands the indication to mobilize…
-
FDA approval · 2019-05-28FDA Approved: MELPHALAN HYDROCHLORIDE — Original Application (Fosun Pharma USA Inc)
FDA approved the original application for melphalan hydrochloride (generic) supplied by Fosun Pharma USA Inc for use in treating multiple my…
-
FDA approval · 2019-02-28FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
The FDA approved a supplemental application for KYPROLIS (carfilzomib) from Onyx Pharmaceuticals, Inc.
-
FDA approval · 2018-11-06FDA Approved: EMPLICITI — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for EMPLICITI (elotuzumab) submitted by E.R. Squibb & Sons, L.L.C.